Immunex' Leukine approved for allogeneic bone marrow transplantation; GM-CSF's fourth indication.
Executive Summary
IMMUNEX LEUKINE APPROVED FOR ALLOGENEIC BMT in HLA-matched related donors Nov. 24. Immunex' yeast-derived granulocyte-macrophage colony stimulating factor (sargramostim) was found to "shorten time to white blood cell count recovery, to decrease the length of hospital stay after the procedure and to reduce the overall incidence of infection," Immunex said Nov. 29.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth